Inventor

WON WALTER

US16 patents

⚠️ This page may combine multiple inventors who share the name “WON WALTER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REVOLUTION MEDICINES INC

7 patents

US10590090B2Mar 17, 2020

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

REVOLUTION MEDICINES INC28 citations92

US10980889B1Apr 20, 2021

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

REVOLUTION MEDICINES INC0 citations60

US11702411B2Jul 18, 2023

Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

REVOLUTION MEDICINES INC0 citations60

US11661401B2May 30, 2023

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

REVOLUTION MEDICINES INC0 citations60

MERCK SHARP & DOHME

6 patents

US10011615B2Jul 3, 2018

Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties

MERCK SHARP & DOHME3 citations71

US10519147B2Dec 31, 2019

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

MERCK SHARP & DOHME1 citations61

US10221167B2Mar 5, 2019

Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels

MERCK SHARP & DOHME1 citations61

US9676780B2Jun 13, 2017

Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties

MERCK SHARP & DOHME2 citations61

US10968210B2Apr 6, 2021

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

MERCK SHARP & DOHME0 citations51

US10688082B2Jun 23, 2020

Aminopyrazine compounds with A2A antagonist properties

MERCK SHARP & DOHME0 citations39

MAZE THERAPEUTICS INC

2 patents

US11814367B2Nov 14, 2023

Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof

MAZE THERAPEUTICS INC4 citations69

US12534453B2Jan 27, 2026

Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof

MAZE THERAPEUTICS INC0 citations57

MERCK SHARP & DOHME LLC

1 patent

US12246008B2Mar 11, 2025

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels

MERCK SHARP & DOHME LLC0 citations51

WON WALTER

REVOLUTION MEDICINES INC

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

C26-linked rapamycin analogs as mTOR inhibitors

C26-linked rapamycin analogs as mTOR inhibitors

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

MERCK SHARP & DOHME

Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Aminopyrazine compounds with A2A antagonist properties

MAZE THERAPEUTICS INC

Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof

Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof

MERCK SHARP & DOHME LLC

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels